Hypothesis

Age‑dependent loss of calbindin‑D28k (CB) in vulnerable neurons is not merely a passive consequence of cellular wear but is actively driven by increased histone deacetylase 2 (HDAC2) binding to the CB promoter, resulting in promoter deacetylation, transcriptional repression, and reduced calcium‑buffering capacity. This epigenetic silencing creates a permissive environment for mitochondrial calcium overload, sustained ER stress, and inflammasome activation, thereby linking calcium dyshomeostasis to neuroinflammatory neurodegeneration.

Mechanistic Rationale

1. HDAC2 upregulation with age – Studies show HDAC2 levels rise in the aging hippocampus and basal forebrain, correlating with memory decline ([2]). HDAC2 deacetylates histone H3K9ac at promoters of neuronal genes, suppressing transcription.

2. Promoter‑specific repression of CB – Chromatin immunoprecipitation followed by qPCR (ChIP‑qPCR) predicts enriched HDAC2 occupancy at the CALB1 (CB) promoter in aged neurons, leading to reduced H3K9ac and lowered CB mRNA and protein ([1]).

3. Consequences of CB loss – Diminished CB elevates cytosolic Ca2+ transients after glutamatergic stimulation, increasing mitochondrial Ca2+ uptake via the MCU. Persistent mitochondrial Ca2+ overload stimulates ROS production and opens the permeability transition pore, triggering cytochrome c release ([5]).

4. ER stress and inflammasome coupling – Elevated ER Ca2+ leak activates PERK‑eIF2α‑ATF4 signaling, upregulating CHOP and sensitizing neurons to apoptosis. Simultaneously, mitochondrial ROS activates the NLRP3 inflammasome in microglia, amplifying neuroinflammation ([6]).

5. Feedback loop – Inflammatory cytokines (IL‑1β, TNFα) further enhance HDAC2 expression via NF‑κB signaling, creating a self‑reinforcing cycle that accelerates CB silencing and neuronal loss.

Testable Predictions

• Prediction 1: In aged mouse basal forebrain cholinergic neurons, ChIP‑seq will show significantly higher HDAC2 occupancy at the CB promoter compared with young controls, accompanied by decreased H3K9ac and CB expression.
• Prediction 2: Pharmacological inhibition of HDAC2 (e.g., with vorinostat) or neuron‑specific HDAC2 knock‑down will restore CB mRNA and protein levels, increase cytosolic calcium buffering capacity, and reduce calcium‑induced mitochondrial ROS in primary neuron cultures.
• Prediction 3: HDAC2 inhibition in vivo will attenuate excitotoxic lesion size after kainic acid administration, lower phospho‑PERK and CHOP levels, and decrease microglial NLRP3 inflammasome activation (ASC speck formation) in the hippocampus.
• Prediction 4: Rescue of CB expression will prevent the formation of neurofibrillary tangles in tau‑overexpressing mice, linking epigenetic CB restoration to reduced Alzheimer‑type pathology.

Experimental Approach

• Perform ChIP‑seq for HDAC2 and H3K9ac in FACS‑sorted basal forebrain cholinergic neurons from 3‑month and 24‑month mice.
• Treat aged mice with vorinostat (50 mg/kg, i.p., three times weekly for 4 weeks) or deliver AAV‑shRNA‑HDAC2 under a Chat promoter.
• Measure CB levels by qPCR and western blot, calcium flux using Fluo‑4 AM imaging, mitochondrial ROS with MitoSOX, ER stress markers (p‑PERK, CHOP), and inflammasome activation (caspase‑1 p20, IL‑1β ELISA).
• Assess neurodegeneration via NeuN staining, stereological neuron counts, and behavioral assays (Morris water maze, novel object recognition).
• In parallel, cross HDAC2‑manipulated mice with tau‑P301S lines to evaluate tangle burden (AT8 immunoreactivity) and cognitive outcomes.

Falsifiability

If HDAC2 inhibition fails to increase CB expression or does not mitigate calcium overload, ER stress, or neuroinflammatory markers despite adequate drug exposure, the hypothesis that epigenetic HDAC2‑mediated silencing drives age‑dependent CB loss would be refuted. Conversely, demonstration that CB restoration occurs without HDAC2 inhibition (e.g., via a HDAC‑independent pathway) would also challenge the proposed mechanism.